These preclinical data suggest that DSF/Cu in combination with alkylating chemotherapy decreases glioma cell invasion and impairs the DNA repair pathways, thereby improving the efficacy of DNA alkylating agents [163].The safety of this approach was demonstrated in a phase 1 trial for recurrent GBM and the efficacy of this combination was investigated in phase 2 trial, which showed limited activity in the unselected IDH-wild type GBM population [245,246]. This evidence concerns the gene IDH1 and glioblastoma.